{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008779","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.409078+00:00","generated_at":"2026-06-01T07:19:57.238926+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA","bullets":["ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).","EHA poster presentation on June 14, 2024 (6:00 PM CEST, Madrid, abstract #P536).","Interim Phase 2 data for prexigebersen (BP1001) plus decitabine/venetoclax in AML show it's well-tolerated with compelling efficacy.","Data from newly diagnosed and refractory/relapsed cohorts both exceeded outcomes with frontline therapy.","No specific numerical results were disclosed in the press releases."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008779","json":"https://secwatch.observer/filing/0001558370-24-008779.json","markdown":"https://secwatch.observer/filing/0001558370-24-008779.md","text":"https://secwatch.observer/filing/0001558370-24-008779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/0001558370-24-008779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024008779/bpth-20240523x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:19:57.238926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}